A Study of Infinatamab Deruxtecan (I-DXd) Alone and in Combination With Other Drugs in People With Prostate Cancer

Full Title

MK-2400-U01 Master Protocol: A Phase 1/2 Platform Study to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan as Monotherapy or in Combination With Other Treatments in Participants With Prostate Cancer

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Susan Slovin’s office at 646-422-4470.

Protocol
26-088
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Susan F. Slovin
Co-Investigators
Matthew Dallos
Diseases
Genitourinary Cancer › Prostate Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06863272
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description